BofA warns Fed risks policy mistake with early rate cuts
Wang Xiaodong, Chair of the Scientific Advisory Board at BeiGene , Ltd. (NASDAQ:BGNE), recently sold American Depositary Shares worth approximately $2,073,826. The transactions took place on March 4, 2025, with share prices ranging from $251.70 to $257.41, near the stock’s 52-week high. According to InvestingPro analysis, BGNE appears overvalued at current levels, despite its impressive 67% revenue CAGR over the past five years. Following these sales, Wang’s indirect ownership includes shares held by Wang Investment LLC and other entities. These transactions were executed under a pre-established Rule 10b5-1 trading plan. With projected revenue growth of 56% for FY2025, investors can access comprehensive valuation metrics and 12+ additional ProTips through InvestingPro’s detailed research report.
In other recent news, BeiGene Ltd (NASDAQ:ONC) reported significant financial results for 2024, highlighting a 55% increase in total revenue, reaching $3.8 billion. The fourth quarter alone saw a 77% rise in product revenue, with the U.S. contributing 55% of these revenues. The company also completed an $800 million manufacturing facility and introduced 13 new molecular entities to the clinic. Looking forward, BeiGene projects 2025 revenue to range between $4.9 billion and $5.3 billion. Additionally, the company aims to achieve GAAP operating breakeven in 2025. In the realm of analyst activity, there were no upgrades or downgrades reported, but firms like Jefferies and Morgan Stanley (NYSE:MS) were actively engaging with BeiGene during their earnings call. These developments underscore BeiGene’s strategic focus on expanding its product pipeline and market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.